Skip to main content
. 2019 Dec 31;1(2):71–77. doi: 10.35772/ghm.2019.01017

Table 1. Target value of antibiotics usage and drug resistant organism*.

Index 2020 (Target Value)**
Proportion of penicillin-resistance in Streptococcus pneumoniae from CSF sample ≤ 15%
Proportion of penicillin-resistance in Streptococcus pneumoniae from samples other than CSF
Proportion of fluoroquinolone resistance in Escherichia coli ≤ 25%
Proportion of methicillin resistance in Staphylococcus aureus ≤ 20%
Proportion of carbapenem resistance in Pseudomonas aeruginosa (Imipenem) ≤ 10%
Proportion of carbapenem (Meropenem) resistance in Pseudomonas aeruginosa ≤ 10%
Proportion of carbapenem (Imipenem) resistance in Escherichia coli ≤ 0.2%
Proportion of carbapenem (Meropenem) resistance in Escherichia coli ≤ 0.2%
Proportion of carbapenem (Imipenem) resistance in Klebsiella pneumoniae ≤ 0.2%
Proportion of carbapenem (Meropenem) resistance in Klebsiella pneumoniae ≤ 0.2%

*Data extracted from Japans National Action Plan on Antimicrobial Resistance 2016-2020 (1). **Proportion of resistant isolates of specific indicator microorganisms in humans (%).